Ambirix Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to global hepatitis burden, childhood vaccination schedules, public health immunization policies, early combination vaccine approvals, school-based vaccination programs.

The growth in the forecast period can be attributed to expanded pediatric coverage, improved vaccine access in emerging markets, long-term immunity benefits, strengthening public health funding, global hepatitis elimination goals. Major trends in the forecast period include growth of combination vaccines, expansion of pediatric immunization programs, rising focus on hepatitis prevention, improved vaccine compliance through fewer doses, government supported vaccination campaigns.

The rising prevalence of hepatitis infections is expected to drive the growth of the ambirix market in the coming years. Hepatitis is the inflammation of the liver, marked by damage to liver cells and impairment of essential liver functions. Hepatitis, particularly hepatitis A and B, continues to pose a global health challenge due to increasing infection rates driven by factors such as poor sanitation, insufficient vaccination coverage, and greater population mobility. Ambirix is a combination vaccine designed to protect against hepatitis A and B infections in individuals aged 1-15 years, offering long-term immunity through a two-dose regimen. It is especially recommended in regions with moderate to high risk of infection. For instance, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, 17,650 new chronic hepatitis B cases were reported in 2023 across 44 states and the District of Columbia, corresponding to a prevalence rate of 6.1 cases per 100,000 people. Therefore, the increasing prevalence of hepatitis infections is driving the ambirix market.

Rising healthcare expenditure is expected to accelerate the growth of the ambirix market going forward. Healthcare expenditure refers to the allocation of financial resources toward health services, including vaccination initiatives and access to combined hepatitis A and B vaccines. It also encompasses total spending on medical services, healthcare goods, and public health programs aimed at preserving and improving population health. Ambirix supports healthcare systems by helping reduce long-term treatment costs associated with hepatitis A and B through effective disease prevention. Its adoption contributes to cost-efficient public health strategies. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with a growth rate of 0.9% in 2022. Additionally, total long-term health and social care expenditure recorded a real-term increase of 2.8% in 2022. Therefore, rising healthcare expenditure is driving the ambirix market.

Growing awareness of pediatric vaccination is expected to support the growth of the ambirix market in the coming years. Pediatric vaccination involves immunizing children to protect them from infectious diseases and plays a vital role in reducing the global burden of preventable illnesses. Awareness of pediatric vaccination is increasing due to public health awareness campaigns, school-based immunization programs, and initiatives by governments and healthcare organizations to promote the benefits of immunization. Vaccines such as Ambirix, which target hepatitis A and B, are critical in protecting children’s health and improving vaccination coverage in regions with historically low immunization rates. For instance, in July 2024, according to a report by the World Health Organization, a Switzerland-based health authority, global coverage of the first dose of the HPV vaccine among girls rose to 27% in 2023, up from 20% in 2022, driven by new vaccine introductions in several countries and the adoption of a one-dose schedule. Therefore, increasing awareness of pediatric vaccination is driving the ambirix market.

Major companies operating in the ambirix market are GSK plc.

North America was the largest region in the ambirix market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ambirix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ambirix market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the ambirix market by increasing costs related to vaccine antigens, vial packaging, and cold chain storage requirements. These impacts are notable in public health procurement and hospital supply chains. Regions dependent on imported vaccines face moderate budget pressure. At the same time, tariffs are encouraging domestic vaccine manufacturing and fill-finish capabilities. This supports sustainable immunization programs over the long term.

The ambirix market research report is one of a series of new reports that provides ambirix market statistics, including ambirix industry global market size, regional shares, competitors with a ambirix market share, detailed ambirix market segments, market trends and opportunities, and any further data you may need to thrive in the ambirix industry. This ambirix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ambirix is a combination vaccine designed to provide protection against both hepatitis A and hepatitis B infections. It contains an inactivated hepatitis A virus along with a purified hepatitis B surface antigen to stimulate an immune response. The vaccine is mainly indicated for individuals aged 1 to 15 years and is administered as a two-dose regimen over a six-month period. It offers long-term protection, helping to reduce the risk of serious liver diseases caused by these viruses.

The primary indication types for ambirix include hepatitis A and hepatitis B. Hepatitis A is a highly contagious liver infection caused by the hepatitis A virus (HAV). The vaccine is distributed through hospitals, pharmacies, and public health programs, and the end users include pediatric and geriatric populations.

The ambirix market consists of sales of single-pack doses, multi-pack doses of pre-filled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.